Cargando…
In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study
Fibroblast growth factor 23(FGF23) is the most important biomarker and pathogenic factor in Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD). In the moderate and severe stages of chronic renal failure, abnormally elevated circulating FGF23 can lead to some complications, including myocardi...
Autores principales: | Kang, Meizi, Chen, Jing, Liu, Lingling, Xue, Cheng, Tang, Xiaojing, Lv, Jiayi, Fu, Lili, Mei, Changlin, Mao, Zhiguo, Liu, Yawei, Dai, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253468/ https://www.ncbi.nlm.nih.gov/pubmed/35801203 http://dx.doi.org/10.3389/fmed.2022.912764 |
Ejemplares similares
-
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017) -
The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis
por: Dörr, Katharina, et al.
Publicado: (2022) -
Improvement of Resistant Hypertension by Nocturnal Hemodialysis in a Patient with End-Stage Kidney Disease
por: Tang, Xiaojing, et al.
Publicado: (2015) -
Cardiac FGF23 expression correlates with left ventricular hypertrophy in patients with chronic kidney disease
por: Leifheit-Nestler, Maren, et al.
Publicado: (2014) -
Nocturnal hemodialysis
por: Ranganathan, D., et al.
Publicado: (2012)